IL269969B2 - 2-pmpa protrope for healthy tissue protection during imaging or radiotherapy of psma-targeted cancer - Google Patents

2-pmpa protrope for healthy tissue protection during imaging or radiotherapy of psma-targeted cancer

Info

Publication number
IL269969B2
IL269969B2 IL269969A IL26996919A IL269969B2 IL 269969 B2 IL269969 B2 IL 269969B2 IL 269969 A IL269969 A IL 269969A IL 26996919 A IL26996919 A IL 26996919A IL 269969 B2 IL269969 B2 IL 269969B2
Authority
IL
Israel
Prior art keywords
compound
formula
accordance
psma
group
Prior art date
Application number
IL269969A
Other languages
English (en)
Hebrew (he)
Other versions
IL269969A (en
Inventor
Barbara Slusher
Michael Nedelcovych
Rana Rais
Clemens Kratochwil
Original Assignee
Univ Johns Hopkins
Adarga Llc
Barbara Slusher
Michael Nedelcovych
Rana Rais
Clemens Kratochwil
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins, Adarga Llc, Barbara Slusher, Michael Nedelcovych, Rana Rais, Clemens Kratochwil filed Critical Univ Johns Hopkins
Publication of IL269969A publication Critical patent/IL269969A/en
Publication of IL269969B2 publication Critical patent/IL269969B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL269969A 2017-04-11 2019-10-11 2-pmpa protrope for healthy tissue protection during imaging or radiotherapy of psma-targeted cancer IL269969B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762484219P 2017-04-11 2017-04-11
PCT/US2018/027106 WO2018191376A2 (en) 2017-04-11 2018-04-11 Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy

Publications (2)

Publication Number Publication Date
IL269969A IL269969A (en) 2022-12-01
IL269969B2 true IL269969B2 (en) 2023-04-01

Family

ID=63792979

Family Applications (1)

Application Number Title Priority Date Filing Date
IL269969A IL269969B2 (en) 2017-04-11 2019-10-11 2-pmpa protrope for healthy tissue protection during imaging or radiotherapy of psma-targeted cancer

Country Status (11)

Country Link
US (1) US20200069706A1 (enExample)
EP (1) EP3609544B1 (enExample)
JP (3) JP2020530007A (enExample)
KR (1) KR102686172B1 (enExample)
CN (1) CN111801121B (enExample)
AU (1) AU2018250609B2 (enExample)
CA (1) CA3059741A1 (enExample)
ES (1) ES3021195T3 (enExample)
IL (1) IL269969B2 (enExample)
SG (1) SG11201909513QA (enExample)
WO (1) WO2018191376A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
HUE066137T2 (hu) 2013-10-18 2024-07-28 Novartis Ag A prosztata-specifikus membrán antigén (PSMA) jelzett inhibitorai, alkalmazásuk képalkotásban és gyógyszerkészítmények prosztatarák kezelésére
JP6464166B2 (ja) 2013-11-14 2019-02-06 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 陽電子放出断層撮影用の化合物
CA3097381A1 (en) 2018-04-17 2019-10-24 Endocyte, Inc. Methods of treating cancer
EP3853213A4 (en) * 2018-09-21 2022-07-06 Endocyte, Inc. Shielding agents and their use
CN120097930A (zh) 2019-05-20 2025-06-06 因多塞特股份有限公司 制备psma缀合物的方法
WO2021202376A1 (en) * 2020-03-30 2021-10-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for blocking uptake of prostate-specific membrane antigen (psma)-targeted radionuclides by exocrine organs
IL297323A (en) * 2020-04-29 2022-12-01 Novartis Ag Methods for radiological labeling of psma-binding ligands and their kits
KR20230002831A (ko) * 2020-04-29 2023-01-05 노파르티스 아게 Psma 결합 리간드의 방사성 표지 방법 및 이의 키트
CA3194592A1 (en) * 2020-10-01 2022-04-07 Neil H. Bander Methods and compositions for increasing uptake, internalization, and/or retention of small molecule ligands
CN113354709B (zh) * 2021-06-03 2023-06-09 江苏华益科技有限公司 一种转移性前列腺癌靶向性药物前体的固相合成方法
CA3258344A1 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals Inc CHELETARIANS AND BIFUNCTIONAL CONJUGATES
WO2023239903A1 (en) * 2022-06-09 2023-12-14 Case Western Reserve University Compositions and methods for preventing retention of psma-targeted therapy
WO2025029946A1 (en) 2023-07-31 2025-02-06 Curium Us Llc [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof
WO2025167998A1 (zh) * 2024-02-06 2025-08-14 北京昌平实验室 膦酸酯骨架的psma靶向偶联物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046294A2 (en) * 2007-10-03 2009-04-09 Cornell University Treatment of proliferative disorders using antibodies to psma
WO2016022827A1 (en) * 2014-08-06 2016-02-11 The Johns Hopkins University Prodrugs of prostate specific membrane antigen (psma) inhibitor
US20160067361A1 (en) * 2014-09-08 2016-03-10 Molecular Insight Pharmaceuticals, Inc. Organ protection in psma-targeted radionuclide therapy of prostate cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10172873B2 (en) 2014-08-06 2019-01-08 The Johns Hopkins University Methods for treating inflammatory bowel disease using prostate specific membrane antigen (PSMA) inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046294A2 (en) * 2007-10-03 2009-04-09 Cornell University Treatment of proliferative disorders using antibodies to psma
WO2016022827A1 (en) * 2014-08-06 2016-02-11 The Johns Hopkins University Prodrugs of prostate specific membrane antigen (psma) inhibitor
US20160067361A1 (en) * 2014-09-08 2016-03-10 Molecular Insight Pharmaceuticals, Inc. Organ protection in psma-targeted radionuclide therapy of prostate cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHATALIC ET AL., TOWARDS PERSONALIZED TREATMENT OF PROSTATE CANCER: PSMA I& T, A PROMISING PROSTATE-SPECIFIC MEMBRANE ANTIGEN-TARGETED THERANOSTIC AGENT, 12 April 2016 (2016-04-12) *
KRATOCHWIL, ET AL, PMPA FOR NEPHROPROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER, 12 December 2015 (2015-12-12) *

Also Published As

Publication number Publication date
WO2018191376A3 (en) 2018-12-27
AU2018250609A1 (en) 2019-10-31
AU2018250609B2 (en) 2024-05-09
US20200069706A1 (en) 2020-03-05
EP3609544C0 (en) 2025-04-09
EP3609544A2 (en) 2020-02-19
JP2020530007A (ja) 2020-10-15
CN111801121A (zh) 2020-10-20
WO2018191376A2 (en) 2018-10-18
EP3609544B1 (en) 2025-04-09
IL269969A (en) 2022-12-01
JP2023093545A (ja) 2023-07-04
ES3021195T3 (en) 2025-05-26
JP2025028897A (ja) 2025-03-05
CN111801121B (zh) 2023-12-01
EP3609544A4 (en) 2020-12-23
KR20200059187A (ko) 2020-05-28
KR102686172B1 (ko) 2024-07-17
CA3059741A1 (en) 2018-10-18
SG11201909513QA (en) 2019-11-28

Similar Documents

Publication Publication Date Title
IL269969B2 (en) 2-pmpa protrope for healthy tissue protection during imaging or radiotherapy of psma-targeted cancer
RU2767664C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
Crown et al. Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma.
EP3148336B1 (en) Eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
RU2587013C2 (ru) Комбинированная химиотерапия
ES2661216T3 (es) Método combinado para tratar el cáncer o un estado precanceroso
US20240082436A1 (en) Synergistic cancer treatment
KR20240110659A (ko) Ｍｄｍ２ 억제제의 간헐적 투여
US20160151406A1 (en) Combination cancer therapy with c-met inhibitors and synthetic oligonucleotides
JP2006528696A (ja) 抗癌剤の抗腫瘍活性を増強する方法
TW202045155A (zh) 用於治療癌症之組合療法
US20220323474A1 (en) Drug combination treatments using bone-targeting therapeutics for bone and bone-related disease
Galligioni et al. Cisplatin and 5-fluorouracil combination chemotherapy in advanced and/or metastatic colorectal carcinoma: a phase II study
WO2008135792A1 (en) Pm00104 compound for use in cancer therapy
US20050197399A1 (en) Method of augmenting the antitumor activity of anticancer agents
JP2025128194A (ja) 哺乳動物の身体におけるｍｙｃ発現腫瘍のタウロリジン治療
US20060258697A1 (en) Method of augmenting the antitumor activity of anticancer agents
JP2025122474A (ja) 腫瘍治療用医薬組成物
KR20240041258A (ko) 종양 혈관 파괴용 약학 조성물
JP2025532719A (ja) 腫瘍血管破壊用医薬組成物
Giovanis Ifosfamide in Small Cell Lung Cancer
HK1202423B (en) Combination therapy with a topoisomerase inhibitor
HK1202419B (en) Combination therapy with a mitotic inhibitor
AU2002225902A1 (en) Methods for contemporaneous administration of levamisole and 5-fluorouracil
EP1343434A1 (en) Methods for contemporaneous administration of levamisole and 5-fluorouracil